Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase i clinical trial

International Journal of Clinical Oncology

Volumn 18, Issue 1, 2013, Pages 87-95

  Doi, Toshihiko ^a   Hamaguchi, Tetsuya ^b   Shirao, Kuniaki ^c   Chin, Kensho ^d   Hatake, Kiyohiko ^d   Noguchi, Kazuo ^e   Otsuki, Tetsuya ^e   Mehta, Anish ^f   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c OITA UNIVERSITY   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e Merck Sharp Dohm Res Labs Japan   (Japan)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gastrointestinal cancer; Histone deacetylase inhibitor (HDACi); Suberoylanilide hydroxamic acid (SAHA); Vorinostat

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLON CANCER; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM CANCER; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; JAPANESE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; GASTROINTESTINAL NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84874108605     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0348-6     Document Type: Article

References (30)

1. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
2. Marks P, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202
3. Timmermann S, Lehrmann H, Polesskaya A et al (2001) Histone acetylation and disease. Cell Mol Life Sci 58:728-736
4. Wang C, Fu M, Mani S et al (2001) Histone acetylation and the cell-cycle in cancer. Front Biosci 6:D610-29, D610-29
5. Ueno M, Toyota M, Akino K et al (2004) Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 25:134-140
6. Murai M, Toyota M, Suzuki H et al (2005) Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 11:1021-1027
7. Kawamura YI, Toyota M, Kawashima R et al (2008) DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 135:142-151
8. Marson CM (2009) Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 9:661-692
9. Butler LM, Agus DB, Scher HI et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170
10. Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39
11. Galanis E, Jaeckle KA, Maurer MJ et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052-2058
12. Secrist JP, Zhou X, Richon VM (2003) HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 4:1422-1427
13. Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210
14. Huang C, Ida H, Ito K et al (2007) Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol 73:990-1000
15. Gordon KJ, Blobe GC (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 1782:197-228
16. Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506-520
17. Ammanamanchi S, Brattain MG (2004) Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J Biol Chem 279:32620-32625
18. Kelly WK, O'Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931
19. Olsen EA, Kim YH, Kuzel TM et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115
20. Fujiwara Y, Yamamoto N, Yamada Y et al (2009) Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci 100:1728-1734
21. Mann BS, Johnson JR, Cohen MH, Justice R et al (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247-1252
22. Rubin E, Agrawal N, Friedman E et al (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 12:7039 doi: 10.1158/1078-0432.CCR-06-1802
23. Gehan EA, Tefft MC (2000) Will there be resistance to the RECIST (response evaluation criteria in solid tumors)? J Natl Cancer Inst 92:179-181
24. Dummer R, Cozzio A, Meier S et al (2006) Standard and experimental therapy in cutaneous T-cell lymphomas. J Cutan Pathol 33(Suppl 1):52-57
25. Nishiyama M, Eguchi H (2009) Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev 61:402-407
26. Luu TH, Morgan RJ, Leong L et al (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a california cancer consortium study. Clin Cancer Res 14:7138-7142
27. Woyach JA, Kloos RT, Ringel MD et al (2009) Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94:164-170
28. Blumenschein GR, Jr, Kies MS, Papadimitrakopoulou VA et al (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26:81-87
29. Lobjois V, Frongia C, Jozan S et al (2009) Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. Eur J Cancer 45:2402-2411
30. Krug LM, Curley T, Schwartz L et al (2006) Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7:257-261